Source link : https://www.newshealth.biz/health-news/adverse-events-differ-between-two-second-line-psoriasis-rxs/
TOPLINE: More gastrointestinal and nervous symptom adverse events (AEs) are linked to apremilast than deucravacitinib, which is associated with more cutaneous AEs, according to a retrospective comparison using US Food and Drug Administration (FDA) data. METHODOLOGY: To evaluate the adverse events associated with apremilast, an oral phosphodiesterase-4 (PDE4) inhibitor, and deucravacitinib, an oral tyrosine kinase […]
Author : News Health
Publish date : 2024-07-25 11:36:04
Copyright for syndicated content belongs to the linked Source.
inHealth